glp-1 drugs ro Diabetes Weight Loss Drugs: Top Options and How They Work Ro launches the GLP-1 Supply

Description

This section will detail the core features of the program and the anticipated payer timelines that dictate when savings will be available to typical patients

Orforglipron Orforglipron, another oral GLP-1RA has being studied extensively for the management of T2DM and Obesity

As is typical for a number of current national and international guidelines, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) 16 recommend that GLP-1 analogues with proven CVD benefit are considered in patients who do not meet individualised glycaemic targets with use of metformin and appropriate lifestyle measures if: atherosclerotic CVD is a major concern there is chronic kidney disease and sodium-glucose cotransporter-2 (SGLT2) inhibitors are not tolerated or contraindicated, and/or there is a compelling need to minimise weight gain and risk of hypoglycaemia in patients without CVD or chronic kidney disease

Long-acting GLP-1RAs also have other benefits including improved gastrointestinal tolerability, moderate plasma drug concentration fluctuations, and more convenient dosage regimens which may improve medication adherence and treatment outcomes [11] (Table 1)